Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Meritxell Ascanio"'
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 19, Iss 1, Pp 1-6 (2024)
Abstract Background This study aimed to assess the comorbidity profile, use of healthcare resources and medical costs of patients with systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) treated at the hospital level in Spain.
Externí odkaz:
https://doaj.org/article/3f8cd62967f14bfcadd1e8146323127f
Autor:
Josep Darbà, Meritxell Ascanio
Publikováno v:
PLoS ONE, Vol 19, Iss 3, p e0298764 (2024)
IntroductionThe goal of this study is to determine the medical costs, comorbidity profile, and health care resources use of patients diagnosed with prostate cancer who have been treated in Spanish hospitals.MethodsThe admission records of the patient
Externí odkaz:
https://doaj.org/article/a665c5eb940a428f98344336ba5e0784
Autor:
Androulla Eleftheriou, Eleni Antoniou, Josep Darbà, Meritxell Ascanio, Michael Angastiniotis, Dimitrios Farmakis
Publikováno v:
Hemoglobin. 46:308-311
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3dd7de4198aeb8998fca19772d54b569
https://doi.org/10.1080/03630269.2023.2167657
https://doi.org/10.1080/03630269.2023.2167657
Autor:
Josep Darbà, Meritxell Ascanio
Objective:This study aimed to assess the comorbidity profile, use of health care resources and med-ical costs of patients with chronic obstructive pulmonary disease (COPD) treated at the hospital levelin Spain.Methods:Admission records of patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dae68c2b1ef61fb160dcc5efbc62971
Autor:
Meritxell Ascanio, Josep Darbà, Antonio Olry de Labry Lima, Josep M. Cruzado, Óscar Díaz Castro, M Belén de la Hija Díaz, Virginia Arroyo Pineda, M de los Reyes García Díaz-Guerra, Jorge M Romero-Requena
Publikováno v:
Clinical Kidney Journal
Dipòsit Digital de la UB
Universidad de Barcelona
Dipòsit Digital de la UB
Universidad de Barcelona
Background Hyperkalaemia (HK) is a common electrolyte disorder in patients with chronic kidney disease (CKD) and/or treated with renin–angiotensin–aldosterone system inhibitors (RAASis). The aim of this study is to determine the severity, current
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99a26c9bf304eaf545c33f664d5a430f
http://europepmc.org/articles/PMC8573009
http://europepmc.org/articles/PMC8573009
Publikováno v:
Journal of Medical Economics. 23:1477-1484
This study reviewed patient characteristics, management, and medical costs of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDSs) in Spanish hospitals.Data were extracted from the Spanish Ministry of Health records via a claims database
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfe24381fbfa0b11fec21bf3c02d038b
https://doi.org/10.1080/13696998.2020.1840180
https://doi.org/10.1080/13696998.2020.1840180
Autor:
Meritxell Ascanio, Josep Darbà
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Universidad de Barcelona
Introduction In the European Union companies only need to demonstrate that the risk-benefit balance of the new drug is favourable to obtain the authorization to sell new drugs. Hence a comparison with available treatments, a cost-effectiveness analys
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d766997f14234d317bd1043581b6384
https://doi.org/10.1016/j.hlpt.2019.02.004
https://doi.org/10.1016/j.hlpt.2019.02.004
Autor:
Meritxell Ascanio, Josep Darbà
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Universidad de Barcelona
Phenylketonuria is a well-known rare disease included in the neonatal screening of many countries. Therefore, there are few published data on the admissions and costs of phenylketonuria in Spain. The objective of this study was to assess the number o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e52ec6ac462f67f7a1116ad0accade7
https://doi.org/10.1007/s40261-019-00760-1
https://doi.org/10.1007/s40261-019-00760-1
Publikováno v:
ClinicoEconomics and Outcomes Research: CEOR
Dipòsit Digital de la UB
Universidad de Barcelona
Dipòsit Digital de la UB
Universidad de Barcelona
Josep Darbà,1 Meritxell Ascanio,2 Jörgen Syk,3– 5 Kjell Alving4 1Department of Economics, Universitat de Barcelona, Barcelona, Spain; 2BCN Health Economics & Outcomes Research, S.L., Barcelona, Spain; 3Department of Neurobiology, Care Sciences an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::489893cdcbc8536ba10b1fe28b1a1ea1
https://pubmed.ncbi.nlm.nih.gov/33935507
https://pubmed.ncbi.nlm.nih.gov/33935507
Publikováno v:
Medicine
Dipòsit Digital de la UB
Universidad de Barcelona
Digital.CSIC. Repositorio Institucional del CSIC
instname
Dipòsit Digital de la UB
Universidad de Barcelona
Digital.CSIC. Repositorio Institucional del CSIC
instname
The rising prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) presents many public health challenges, including a substantial impact on healthcare resource utilization and costs. There are important regiona
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e62141b88bc198fab04c57558006482a
https://pubmed.ncbi.nlm.nih.gov/33327291
https://pubmed.ncbi.nlm.nih.gov/33327291